JNJ logo Johnson & Johnson +
Johnson & Johnson
+

Johnson & Johnson (JNJ) Business News

Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:34 AM | Thursday | Jun 4, 2026 PRNewsWire

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

News Thumbnail
12:04 AM | Wednesday | Jun 3, 2026 PRNewsWire

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

News Thumbnail
12:03 AM | Wednesday | Jun 3, 2026 PRNewsWire

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

News Thumbnail
8:39 AM | Sunday | May 31, 2026 GlobeNewsWire

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

News Thumbnail
8:29 AM | Sunday | May 31, 2026 PRNewsWire

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

News Thumbnail
8:27 AM | Sunday | May 31, 2026 PRNewsWire

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

News Thumbnail
8:18 AM | Friday | May 29, 2026 PRNewsWire

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

News Thumbnail
7:00 AM | Thursday | May 21, 2026 Business Wire

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

News Thumbnail
9:00 AM | Tuesday | May 19, 2026 Business Wire

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

News Thumbnail
7:45 AM | Tuesday | May 12, 2026 Business Wire

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

News Thumbnail

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

PRNewsWire

6:34 AM | Thursday | Jun 4, 2026

news photo
Loading...

Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercialization Board strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investors BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing. Piper Sandler Merchant Banking led the financing with participation from Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic, along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.

Read full article redirect
6:34 AM | Thursday | Jun 4, 2026

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

PRNewsWire

Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercialization Board strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investors BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing... Read more

Read full article arrow
News Thumbnail
12:04 AM | Wednesday | Jun 3, 2026

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

PRNewsWire

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to... Read more

Read full article arrow
News Thumbnail
12:03 AM | Wednesday | Jun 3, 2026

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

PRNewsWire

Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and pain Nipocalimab is the only FcRn blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. FDA for the treatment of adults with moderate-to-severe Sjögren's disease. LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker... Read more

Read full article arrow
News Thumbnail
8:39 AM | Sunday | May 31, 2026

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

GlobeNewsWire

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death 1

Read full article arrow
News Thumbnail
8:29 AM | Sunday | May 31, 2026

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

PRNewsWire

More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication  RYBREVANT FASPRO™,  an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting  Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication  CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses.

Read full article arrow
News Thumbnail
8:27 AM | Sunday | May 31, 2026

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

PRNewsWire

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death  Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease. The trial met both primary endpoints.

Read full article arrow
News Thumbnail
8:18 AM | Friday | May 29, 2026

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

PRNewsWire

Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second line TECVAYLI® delivered deep and durable responses with nearly two-thirds of patients achieving a complete response or better CHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with TECVAYLI® (teclistamab-cqyv) versus standard of care regimens in patients with relapsed or refractory multiple myeloma treated as early as second line. In a patient population whose myeloma was predominantly refractory to anti-CD38 therapy and lenalidomide,... Read more

Read full article arrow
News Thumbnail
7:00 AM | Thursday | May 21, 2026

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience. Integrating Johnson & Johnson's Polyphonic™ o.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | May 19, 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Business Wire

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, today announced that Johnson & Johnson has secured naming rights to the Johnson & Johnson Exchange at the New Jersey Innovation Hub (NJIH), Powered by Portal Innovations. The collaboration reinforces Johnson & Johnson's longstanding leadership in advancing innovation, entrepreneurship, and the life sciences sector in New Jersey, one of the nation.

Read full article arrow
News Thumbnail
7:45 AM | Tuesday | May 12, 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

Read full article arrow
News Thumbnail